## TESTING OF THE GUIDANCE ON RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Caribbean Training Course on Risk Assessment of LMOs, Belize City, Belize, 26-30 September 2011

#### PARTICIPANT 1

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good
Please indicate the level of agreement you attribute to each	ach of the question	is in the left co	lumn.		
Q5. How do you evaluate the level of consistency of Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?				$\boxtimes$	
Q6. How do you evaluate the usefulness of the Guida as a tool to assist countries in conducting and reviewing assessments of LMOs in <u>a scientifically sound and case-case manner</u> ?	risk				
Q7. How do you evaluate the usefulness of the Guida as a tool to assist countries in conducting and reviewing assessments of LMOs introduced into various receiving environments?					
PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS					
Please answer each of the questions in the left column w	vith "yes" or "no"	' and add comn	ients if needed.		
Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments:	<type here=""></type>		
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	⊠ Yes □ No	Comments:	<type here=""></type>		
Q10. Is the Roadmap organized in a logic and structured manner?	⊠ Yes □ No	Comments:	<type here=""></type>		
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No		The inclusion o ld be useful in t		Jse of
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	⊠ Yes □ No		More examples en, however.	of non-plant	LMOs
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	⊠ Yes □ No		However, it app ases as opposed		ewed

Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	☐ Yes ⊠ No	Comments: <type here=""></type>
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	⊠ Yes □ No	Comments: It could be based more on summaries and less reliant on words since reference can be made to the specifics in the document itself.

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good
Please indicate the level of agreement you attribute to each of the questions in the left column.					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?				$\boxtimes$	
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner</u> ?			$\boxtimes$		
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments?				$\boxtimes$	

#### PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	⊠ Yes □ No	Comments: <type here=""></type>
Q10. Is the Roadmap organized in a logic and structured manner?	☐ Yes ☐ No	Comments: It is logical however the structure could be improved.
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: But it could be improved.
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	☐ Yes ⊠ No	Comments: There is some lack of info on the use of it in relation to animals.
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	⊠ Yes □ No	Comments: <type here=""></type>

Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	☐ Yes ☐ No	Comments: <type here=""></type>
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	⊠ Yes □ No	Comments: It is however too wordy.

Q10. Is the Roadmap organized in a logic and

Q11. Is the Roadmap user-friendly taking into

Q12. Is the Roadmap applicable to all types of

LMOs (e.g. plants, animals, microorganisms)?

account that risk assessment is a complex scientific

structured manner?

and multidisciplinary activity?

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good
Please indicate the level of agreement you attribute to ea	ch of the question	is in the left co	lumn.		
Q5. How do you evaluate the level of consistency of a Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?	the				$\boxtimes$
Q6. How do you evaluate the usefulness of the Guida as a tool to assist countries in conducting and reviewing r assessments of LMOs in <u>a scientifically sound and case-te case manner</u> ?	risk 🗖				
Q7. How do you evaluate the usefulness of the Guida as a tool to assist countries in conducting and reviewing a assessments of LMOs introduced into various receiving environments?					
PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS					
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.					
Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments:	<type here=""></type>		
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	⊠ Yes □ No	however it n limited expe of the works process. For knowledge b	The Roadmap is nay be of limite- rience or knowl hop, which con assessors with basis, it should be to a large exten	d use to assess ledge. We had abined, made even a smalle be very useful	sors with l the benefit sense of the r

Xes Yes

🗌 No

Xes Yes

🗌 No

Xes Yes

🗌 No

Comments: <Type here>

Comments: <Type here>

Comments: <Type here>

Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	⊠ Yes □ No	Comments: <type here=""></type>
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	☐ Yes ⊠ No	Comments: <type here=""></type>
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	⊠ Yes □ No	Comments: <type here=""></type>

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good
Please indicate the level of agreement you attribute to each of the questions in the left column.					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?					$\boxtimes$
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner</u> ?					
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments?					

#### PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	⊠ Yes □ No	Comments: <type here=""></type>
Q10. Is the Roadmap organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	☐ Yes ⊠ No	Comments: More emphasis is placed on plants and more needs to be placed or it needs to be extended to include animals.

Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	☐ Yes ⊠ No	Comments: <type here=""></type>
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	☐ Yes ⊠ No	Comments: <type here=""></type>
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	⊠ Yes □ No	Comments: <type here=""></type>

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good
Please indicate the level of agreement you attribute to each of the questions in the left column.					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?				$\boxtimes$	
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner</u> ?					
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments?					

## PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments: It provides a logical and sequencial approach to the process.
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	⊠ Yes □ No	Comments: <type here=""></type>
Q10. Is the Roadmap organized in a logic and structured manner?	⊠ Yes □ No	Comments: I think it does.
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: The map helps to simplify a complex task into a simple process.
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	⊠ Yes □ No	Comments: With some minor variations to non-plant LMOs.

Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	⊠ Yes □ No	Comments: <type here=""></type>
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	⊠ Yes □ No	Comments: Where examples are made, it should also include the non-plant LMOs.
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	⊠ Yes □ No	Comments: But a little too heavy with wording in the boxes.

OVERALL E	VALUATI	ON			
	Very poor	Poor	Neutral	Good	Very good
Please indicate the level of agreement you attribute to each of the	e questions	in the left col	umn.		
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?					$\boxtimes$
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner</u> ?					
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments?					

## PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	⊠ Yes □ No	Comments: <type here=""></type>
Q10. Is the Roadmap organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	□ Yes ⊠ No	Comments: <type here=""></type>

Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	⊠ Yes □ No	Comments: <type here=""></type>
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	☐ Yes ⊠ No	Comments: <type here=""></type>
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	□ Yes ⊠ No	Comments: Too much writing in the text boxes distracting from the representativeness of the graphic flow. The depiction of overarching issues in the flowchart does not depict its "overarchedness" adequately.

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good
Please indicate the level of agreement you attribute to each of the questions in the left column.					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?				$\boxtimes$	
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner</u> ?					
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving</u> <u>environments</u> ?				$\boxtimes$	

## PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>
Q9. Is the Roadmap useful to risk assessors who	Tes Yes	Comments: The Roadmap is only useful for risk assessors that have a certain amount of experience with the used wording in the Protocol and in this particulat type of risk assessment.
have limited experience with LMO risk assessment?	🛛 No	For persons of mostly developing countries like in the Caribbean this Roadmap can be understood after first introducing the concepts of risk assessment of LMOs through training.
Q10. Is the Roadmap organized in a logic and structured manner?	X Yes	Comments: <type here=""></type>

	🗌 No	
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	⊠ Yes □ No	Comments: The applicability of this Roadmap is highly dependent on experiences that have already been acquired through earlier risk assessments on LMOs.
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	⊠ Yes □ No	Comments: The applicability of this Roadmap is highly dependent on experiences that have already been acquired through earlier risk assessments on LMOs.
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	☐ Yes ⊠ No	Comments: <type here=""></type>
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	☐ Yes ⊠ No	Comments: The text under the headings in my opinion is too much and adds no firther value to the chart.
		All relevant text is in the Guidance and does not need repeating in the chart.

-----